Literature DB >> 20923684

Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation.

Beatriz Rodríguez-Bayona1, Ana Ramos-Amaya, José A Brieva.   

Abstract

Plasma cells (PCs) are specialized in antibody (Ab) production and they are, therefore, responsible for maintaining humoral immune responses. The human PC compartment is heterogeneous. PCs from inductive secondary lymphoid organs and from peripheral blood (PB) show less capability for prolonged survival and Ab production than bone marrow (BM) PCs, a pool consisting of fully mature cells. The HLDA9 workshop has allowed the use of labeled-monoclonal Abs (moAbs) recognizing a variety of recently identified lymphocyte modulatory surface receptors. In this study, flow cytometry analysis has been used to define the presence of these receptors on human PCs obtained from human tonsil (as an example of inductive organ), from PB and from BM. It was found that human PCs commonly expressed SLAMF1 (CD150), SLAMF2 (CD48), SLAMF3 (CD229), SLAMF6 (CD352) and SLAMF7 (CD319), but not SLAMF4 (CD244). In addition, PCs distinctively showed a low level of SLAMF5 (CD84) and a very high level of SLAMF7 expression in comparison with earlier stages of B cell maturation. All PC subsets exhibited a similar pattern of expression of SLAMF receptors suggesting a stage-dependent role for these proteins. In addition, most circulating PCs clearly expressed TNFRSF14 (CD270), BTLA (CD272), B7-1 (CD80) and B7-2 (CD86), and a substantial fraction of them were also positive for TNFRSF18 (CD357), FCRL1 (CD307a) and LAIR-1 (CD305). In contrast, tonsil and BM PCs only exhibited partial expression of TNFRSF14 and B7-2, a pattern of molecular expression similar to that detected on germinal center (GC) B cells. Present results indicate that human PCs exhibit a common pattern of SLAMF proteins, but differ in the rest of the receptors examined; this difference might be associated with their distinctive homing and functional requirements.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923684     DOI: 10.1016/j.imlet.2010.09.015

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  Repository corticotrophin injection exerts direct acute effects on human B cell gene expression distinct from the actions of glucocorticoids.

Authors:  A L Benko; C A McAloose; P M Becker; D Wright; T Sunyer; Y I Kawasawa; N J Olsen; W J Kovacs
Journal:  Clin Exp Immunol       Date:  2018-01-12       Impact factor: 4.330

2.  The transcriptional profiling of human in vivo-generated plasma cells identifies selective imbalances in monoclonal gammopathies.

Authors:  Luis M Valor; Beatriz Rodríguez-Bayona; Ana B Ramos-Amaya; José A Brieva; Antonio Campos-Caro
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

3.  CD39 and CD326 Are Bona Fide Markers of Murine and Human Plasma Cells and Identify a Bone Marrow Specific Plasma Cell Subpopulation in Lupus.

Authors:  Van Duc Dang; Elodie Mohr; Franziska Szelinski; Tuan Anh Le; Jacob Ritter; Timo Hinnenthal; Ana-Luisa Stefanski; Eva Schrezenmeier; Soeren Ocvirk; Christian Hipfl; Sebastian Hardt; Qingyu Cheng; Falk Hiepe; Max Löhning; Thomas Dörner; Andreia C Lino
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

4.  The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.

Authors:  Inna Gordiienko; Larysa Shlapatska; Valeriia Kholodniuk; Lilia Sklyarenko; Daniel F Gluzman; Edward A Clark; Svetlana P Sidorenko
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

5.  Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus.

Authors:  Maria P Karampetsou; Denis Comte; Katalin Kis-Toth; Vasileios C Kyttaris; George C Tsokos
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.